Form 4: Cadrenal Therapeutics CEO Sells Shares

Cadrenal Therapeutics CEO and Chairman Quang Pham reported the sale of 1,300 shares of common stock through pre-arranged Rule 10b5-1 trading plans.

Summary

• Quang Pham, CEO and Chairman of Cadrenal Therapeutics, Inc. (CVKD), reported sales of common stock.
• Transactions occurred on September 29, 2025, and October 1, 2025.
• A total of 1,300 shares were sold directly by Mr. Pham.
• The sales were executed under a Rule 10b5-1 trading arrangement.
• The weighted average sale price for both transactions was $14.01 per share.
• Following these transactions, Mr. Pham directly beneficially owns 202,633 shares of common stock.
• Additionally, Mr. Pham indirectly beneficially owns 200,000 shares through The PVBQ Living Trust, where he is the Trustee and his child is the sole beneficiary.

Sentiment

Score: 5

Explanation: The sale of shares by a key executive is generally viewed with caution, but the execution under a Rule 10b5-1 plan mitigates immediate negative sentiment as it indicates a pre-scheduled transaction rather than a reaction to new adverse information. The executive retains significant direct and indirect ownership.

Positives

• The sales were conducted under a Rule 10b5-1 trading arrangement, indicating a pre-planned transaction rather than a reaction to recent negative company developments.
• Quang Pham retains substantial direct and indirect beneficial ownership, totaling 402,633 shares, demonstrating continued alignment with shareholder interests.

Negatives

• Insider sales, even if pre-planned, can sometimes be perceived negatively by the market as they reduce the insider's direct stake in the company.

Risks

• Potential negative market perception or investor sentiment due to insider share sales, which could put downward pressure on the stock price.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
• Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and disposition power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.

Industry Context

This filing is a routine insider transaction report and does not provide specific information to analyze broader industry trends or competitive landscape. Insider sales are common across all industries, and their interpretation often depends on the specific circumstances and the insider's overall holdings.

Comparison to Industry Standards

• This filing reports standard insider trading activity under a Rule 10b5-1 plan. Such plans are widely used by executives across various industries to manage personal stock holdings and avoid accusations of trading on material non-public information.
• The reported sales volume of 1,300 shares represents a small fraction of Mr. Pham's total beneficial ownership (over 400,000 shares), which is not uncommon for executives diversifying their portfolios or managing liquidity.

Related Party Transactions

• Quang Pham indirectly beneficially owns 200,000 shares through The PVBQ Living Trust, where he is the Trustee and his child is the sole beneficiary. This represents a related party holding.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, though the 10b5-1 plan suggests it's not based on new information. The relatively small number of shares sold compared to total holdings might limit significant concern.

Next Steps

• The filing does not specify any future actions, events, or milestones for the company or the reporting person beyond the reported transactions.

Key Dates

Recommendation

The Form 4 filing indicates routine insider sales executed under a Rule 10b5-1 trading plan. While insider sales can sometimes be a negative signal, the pre-arranged nature of these transactions suggests they are not based on new, adverse material information. The CEO retains a substantial stake in the company, both directly and indirectly. Without additional company-specific news or broader market context, this filing alone does not provide sufficient grounds for a strong buy or sell recommendation, thus a 'hold' position is appropriate to observe further developments.

Keywords

Cadrenal Therapeutics, CVKD, Quang Pham, Form 4, insider trading, stock sale, 10b5-1 plan, CEO, Director, beneficial ownership